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Abstract
After some well-publicised problems with paediatric cardiac surgery, there has been great interest
in England in monitoring clinical quality in specialised medical services. The National Commissioning
Group plans, funds and monitors a set of highly specialised services for the National Health Service
in England. We have developed systems for monitoring clinical quality that perform two
interrelated but distinct functions: performance measurement and performance improvement. The
aim is to collect information on all patients seen during each year – a 100% consecutive case series.
Generally, there is no conceptual difficulty identifying an appropriate outcome for surgical
interventions: the indication for surgery usually defines the outcome to monitor. This is not so for
the medical and psychiatric services, where the relevant outcome to monitor is sometimes not
obvious. There are a number of problems in interpreting, and acting on, outcome data for rare
conditions and treatments. These problems include statistical problems due to small numbers, the
need to risk adjust data and coding problems.
Introduction
After some well-publicised problems with paediatric car-
diac surgery in Bristol [1], there has been great interest in
England in monitoring clinical quality in specialised med-
ical services. The National Commissioning Group [2]
plans, funds and monitors a set of highly specialised serv-
ices for the National Health Service in England. These
services fall into three groups: surgical interventions; med-
ical or psychiatric care; and diagnostic procedures. We
have developed a system of monitoring these services
which we describe and discuss in this paper.
In developing and implementing systems for monitoring
clinical quality we have appreciated that they perform two
interrelated but distinct functions: performance measure-
ment and performance improvement. The purpose of per-
formance measurement is to ensure that all the centres
involved in providing a service are offering equivalent
quality. Promoting performance improvement through
review of outcome data is equally important.
In rare disease services we are dealing with complex multi-
component interventions. The number of patients is so
small that learning is unlikely to occur spontaneously
[3,4]. This is true even if we network at a health system
level. Therefore, we need mechanisms to actively drive
learning [3,4]. Learning will not happen passively, partic-
ularly in isolated single centres. The aim of our process for
monitoring outcomes is to contribute to developing
expertise and quality.
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Methods
For the surgical and medical group of services, the aim is
to collect information on all patients seen during the year
– a 100% consecutive case series. For each service, specific
outcome measures are chosen based on the characteristics
of the disease and the service. The main measures are set
out in Tables 1, 2, 3. When collecting outcome data we use
the following definitions:-
￿ Deaths – actual number of patients who died within a
set time period after the intervention e.g. three months.
￿ Survival – number and/or % of patients surviving within
a set time period after the intervention
￿ Mortality – number and/or % of patients dying within a
set time period after the intervention
￿ Median survival – the time period that 50% of patients
survive after the intervention
The data collected must be important to the centres them-
selves. They must regard data as a means to ensure they are
aware of their own performance related to the national
service as a whole. In practice, services usually become
aware of an unexpected run of worse outcomes before
data is formally analysed, but at a minimum the data col-
lection is necessary in case a centre does not recognise a
worsening of results. Collection and analysis of outcome
over time is particularly important to put into context
newly arisen concerns about performance at an individual
centre.
We do not impose outcome measures unilaterally, but
agree them with clinicians who provide the services.
Imposition of measures without agreement may impair
the constructive relationship between commissioners and
the services, reduce compliance, become a mechanical
exercise resented by the services and possibly lead to per-
verse incentives, such as not treating high-risk patients.
Agreement on outcomes also involves reassurance about
how we will interpret and use data on small numbers of
patients. A sceptic might argue that it is harmful to collect
outcome data because of the risk of misinterpretation. On
the other hand, data may, in spite of all its limitations,
suggest a possible difference in outcomes that needs fur-
ther exploration. The important thing is that the services
trust us to use the data sensibly.
In surgical services, the commonest outcome monitored is
survival, though sometimes another measure is more
appropriate: for example, visual acuity after an eye proce-
dure, or local recurrence after surgery for bone sarcoma.
Generally, there is no conceptual difficulty identifying an
appropriate outcome for surgical interventions: the indi-
Table 1: Clinical outcomes used as indicators to assess the performance of surgical services
Condition or Intervention Outcome measure
Bladder exstrophy Immediate complications
Bone cancer Three-year local recurrence
Adult Ventricular Assist Devices (Bridge to heart transplant) Survival
Child Ventricular Assist Devices/Extracorporeal Membrane 
Oxygenation (ECMO) (Bridge to heart transplant)
Deaths
Complex tracheal disease Deaths, Re-intervention, Stents, Repeated outpatient attendances, 
Repeated inpatient attendances.
Craniofacial surgery Appropriate measure not clear
Extracorporeal Membrane Oxygenation (ECMO) (adult) Survival without severe disability at 6 months
Extracorporeal Membrane Oxygenation 
(ECMO) (neonate & infants, children)
Survival to discharge
Malformation of female genital tract Research study published: 20-year outcome on sexual function [22].
Ocular oncology Loss of eye (primary and secondary enucleation); Local recurrence.
Oculo-odonto-kerato-prosthesis Visual acuity
Pseudomyxoma of peritoneum Complications, median survival
Pulmonary thromboendarterectomy In-hospital mortality
Retinoblastoma Deaths; Loss of eye (primary and secondary enucleation); Metastasis.
Severe Combined Immunodeficiency Deaths
Transplant – heart Mortality at 30 days after transplant; Survival one and five years after 
transplant
Transplant – liver Mortality at 90 days after transplant; Survival five years after transplant
Transplant – lung Mortality at 90 days after transplant; Survival one and five years after 
transplant
Transplant – pancreas Mortality at 90 days after transplant; Survival five years after transplant
Transplant – small bowel Mortality at 90 days after transplant; Survival five years after transplant
Vein of Galen malformation Deaths and disabilityOrphanet Journal of Rare Diseases 2008, 3:23 http://www.ojrd.com/content/3/1/23
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cation for surgery usually defines the outcome to monitor.
This is not so for the medical and psychiatric services,
where the relevant outcome to monitor is sometimes not
obvious. In one or two services, a well-validated scale is
available to track improvement in the patient's disease.
Thus the Yale-Brown Obsessive Compulsive Score
(YBOCS) [5-7] meets this requirement. Before and after
treatment scores can be used to monitor the effectiveness
of treatment in the service for obsessive compulsive disor-
der (Figure 1).
Although all services aim to improve quality of life for
patients, two problems arise where no disease-specific val-
idated scale exists. Firstly, a generic measure may not be
sensitive to the type of change one can realistically expect,
even from a high quality service, in a condition with no
option for disease modifying treatment. Epidermolysis
bullosa provides an example of this. Secondly, generic
quality of life scores are expensive (many are protected by
copyright) and time consuming to administer. Hence bio-
chemical proxies, though imperfect, may have to do duty
as measures of the quality of medical care. Indices of gly-
caemic control in Alstrom syndrome are an example [8,9].
In the diagnostic services, the 'outcome' is a correct diag-
nosis. But since these are the national diagnostic centres,
the diagnosis they make is, in one sense, the 'correct' diag-
nosis by definition. Hence, our focus in these services is to
ensure participation in external quality assurance (EQA)
schemes, together with a laboratory inspection system.
So far we have discussed outcome in patients who have
attended a specialised service. But in a national system of
care, we need also to check that the centres are serving the
entire population of the country, and not just those who
live nearby, since distance between referrer and special-
ised centre can be a barrier to care [10,11]. To examine
this we use geo-spatial maps created in MapInfo©.
Results
Within this section we will use, as examples, data from
several services we commission. Outcome data collection
and analysis should also be used more broadly as part of
joint national audit involving all the centres for a particu-
lar service. The centres involved in each service are
expected to meet as a whole at least once per year in a for-
mal audit day. Here they present individual centre and
joint national audits, share experiences and discuss the
outcome data on all patients seen during the most recent
year (or years if the numbers are very small) – the 100%
consecutive case series (Figure 1 and Table 4). In this proc-
ess, centres compare outcomes, discuss apparent differ-
ences and learn from each other (Table 5). This is vital in
services involving small numbers of patients and impor-
tant but rarely seen complications [3,4,12].
Table 2: Clinical outcomes used as indicators to assess the performance of medical treatment and mental health
Condition or Service Outcome measure
Alstrom syndrome Appropriate measure not clear, there are biochemical markers of quality of care.
Chorioncarcinoma Deaths
Epidermoloysis bullosa Appropriate measure not clear, there are biochemical markers of quality of care.
Intestinal failure Annual mortality
Lysosomal storage disorders Quality of life scales currently in development
Mental health service for deaf adolescents Global function score
Obsessive compulsive disorder Yale-Brown Obsessive Compulsive Score
Paediatric liver disease Heterogeneous category: five marker conditions are under consideration; 
Hepatoblastoma, Biliary atresia, Tyrosinaemia, Autoimmune sclerosing cholangitis, 
Bile acid disease. For all of these survival is the outcome indicator.
Paediatric pulmonary hypertension Survival
Persistent Hyperinsulinemic hypoglycaemia of infancy (PHHI) Survival and disability
Secure forensic mental health service: for young people Health of the Nation Outcome Scales for Children and Adolescents (HONOSCA) 
and; Health of the Nation Outcome Scales (HONOS) Secure plus global function
Table 3: Clinical outcomes used as indicators to assess the performance of diagnostics
Condition Outcome measure
Amyloidosis External Quality Assurance Services (EQAS) plus external inspection
Mitochondrial disorders External Quality Assurance Services (EQAS) plus external inspection
Ophthalmic pathology External Quality Assurance Services (EQAS) plus external inspection to be arranged
Primary ciliary dyskinesia To be determined
Rare neuromuscular disorder External Quality Assurance Services (EQAS) plus external inspectionOrphanet Journal of Rare Diseases 2008, 3:23 http://www.ojrd.com/content/3/1/23
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The true prevalence and spatial distribution of many very
rare diseases is not known. When examining the geo-
graphical access to services, our working assumption is
that case ascertainment is likely to be most complete near
a specialised centre where awareness is high (Figure 2);
and that low rates distant from the centre are evidence of
poor access until proven otherwise (Figure 3).
Poor access may be a result of travel difficulties or failure
by local clinicians to recognise patients in need of highly
specialised care. Where a clear geographical inequity in
service use is found, options for action include the devel-
opment of collaborative arrangements with a local hospi-
tal, the commissioning of a new specialised centre or,
where appropriate, increasing awareness in non-referring
regions.
Discussion
There are a number of problems in interpreting, and act-
ing on, outcome data for rare conditions and treatments.
The first group of issues are statistical. For some services,
even though the National Health Service in England has a
population base of 50 million patients, there are too few
patients for meaningful statistical analysis. Examples
include congenital hyperinsulinism, bladder exstrophy
and the Vein of Galen malformation.
A further problem, particularly when centres are com-
pared with each other, is interpretation of crude outcome
data that are not adjusted for risk. This is especially diffi-
cult for conditions such as retinoblastoma, where on aver-
age there are only 50 new patients in the UK each year,
two types – bilateral and unilateral – with different under-
lying genetics, and four clinical grades relevant to treat-
ment and preserving vision.
Graph showing change in YBOC score Figure 1
Graph showing change in YBOC score. Patients with OCD/BDD admitted to Heather Ward, South West London and St 
George's Mental Health NHS Trust April 2007 to April 2008, with YBOC score at admission and at discharge or dropout.
Table 4: Visual acuity results after Osteo-Odonto-
Keratoprosthesis (OOKP) surgery
Result Number of Patients
> 6/12 19
6/18 – 6/60 9
< 6/60 2
No Improvement 6
Source: [23]Orphanet Journal of Rare Diseases 2008, 3:23 http://www.ojrd.com/content/3/1/23
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Where numerical analysis is possible, other issues arise.
One example is the alert threshold at which further inves-
tigation is needed. This could be a relative or an absolute
threshold, for example a 10% difference in death rates or
an excess of 5 deaths above expectation. Setting such
thresholds is arbitrary and needs to be agreed with the
services. We have little experience of making these judge-
ments for outcomes other than mortality – it is not clear
what difference in quality of life outcomes, for example,
should trigger further action.
In services with more than one centre we look to see that
there are no statistically significant differences in outcome
between the centres (Table 5). For services with one centre
we can determine whether or not the centre meets an
agreed outcome threshold. In the Osteo-Odonto-Kerato-
prosthesis (OOKP) surgery service (Table 4) the agreed
threshold is a post-operative visual acuity of 6/12 or better
in at least 50% of patients.
'Expectation' may be set against the unit's own historic
performance, using a sequential test analysis such as the
variable life adjusted display (VLAD) [13,14], or the com-
parator may be based on the overall performance of all
units providing the same service [15]. In practice these
analyses are performed only for transplant services where
the volume of data is large enough, for example, for adult
liver and cardiothoracic transplant. These analyses are per-
formed by our colleagues at the national transplant organ-
isation [16] and by an academic unit within the Royal
College of Surgeons [17]. Whatever expectation is chosen,
problems of Type I and Type II errors remain in judging
the true meaning of any statistically significant difference
from expectation. There are other statistical techniques for
examining rare adverse events that may be useful, such as
g-type statistical control charts [18,19], but as yet we have
no experience of using these.
Ideally, we would like also to compare results at UK cen-
tres with the best international centres. This is rarely pos-
sible. Publications in the international literature are
almost always focused on selected subsets of the centre's
caseload rather than a 100% consecutive case series. Fur-
thermore, problems of comparability remain because the
centres in England, unlike those elsewhere, have responsi-
bility for all cases arising in England whereas specialised
centres in other health systems almost always have
selected caseloads. In addition, case-mix and threshold for
intervention may not be the same.
Our generic approach for investigating apparent change or
differences in outcome is to initiate a case note audit. If
problems are detected, the centres may change their clini-
cal practice appropriately. For example a transplant centre
may change its donor or recipient eligibility criteria; or a
surgical service may change its anticoagulant regime. If
problems persist and are clearly intractable, then we may
as a last resort request or require a centre to stop providing
the service.
Mapping patient attendance at specialised centres has
been discussed above. More properly when we consider
mapping data, we should measure, not just access to the
specialised service, but health outcomes. This potentially
takes two forms. First is the relationship between distance
to treatment centre and health outcome. We have not yet
used the geospatial data for this purpose. The second way
to look at health outcomes is to examine data for the
whole population of England, whether or not the special-
ised service has been accessed. This is only feasible where
mortality, or perhaps median age at death, is a relevant
outcome. Median age at death has been used, for example,
to judge the success of national health systems in caring
for people with cystic fibrosis [20].
Where geographical inequities persist, there are a number
of possible actions. These include educational initiatives,
development of outreach or shared care arrangements
between local services and the specialist centre, and estab-
lishing a new centre.
For the very rare conditions in the English national com-
missioning system, coding is a major obstacle to retrieving
the necessary mortality data. Almost none have their own
Table 5: Patient mortality by liver transplant centre for all adult patients between 1st March 1994 and 31st March 2006 in England.
Centre Total 90-day mortality % (95% CI) 5-Year mortality % (95% CI)
A 342 9.1 (6.5 – 12.6) 27.0 (22.2 – 32.5)
B 908 10.8 (9.0 – 13.0) 31.2 (27.8 – 34.9)
C 663 6.5 (4.9 – 8.7) 24.8 (21.3 – 28.7)
D 616 11.5 (9.3 – 14.3) 30.1 (26.4 – 34.2)
E 1247 6.1 (4.9 – 7.6) 26.9 (24.1 – 30.0)
F 1268 10.6 (9.1 – 12.5) 24.5 (22.1 – 27.2)
Source: [24]
Patient mortality by transplant centre up to 5 years post liver transplant for all adult patients who received a first liver transplant as elective 
between 1st March 1994 and 31st March 2006 in EnglandOrphanet Journal of Rare Diseases 2008, 3:23 http://www.ojrd.com/content/3/1/23
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Map of new amyloid referrals per 1 million population by English Strategic Health Authority 2007–08 Figure 2
Map of new amyloid referrals per 1 million population by English Strategic Health Authority 2007–08. This map 
of new amyloid referrals to the specialist service covers England only and not Scotland, Northern Ireland or Wales.Orphanet Journal of Rare Diseases 2008, 3:23 http://www.ojrd.com/content/3/1/23
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Map of Transplants for Severe Combined Immunodeficiency per 1 million population by English Strategic Health Authority  2006–07 Figure 3
Map of Transplants for Severe Combined Immunodeficiency per 1 million population by English Strategic 
Health Authority 2006–07. This map of transplants for severe combined immunodeficiency covers England only and not 
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ICD code, but are included in larger categories (e.g. ICD-
10 E75.2 includes Fabry's, Gaucher, Krabbe, Niemann-
Pick, Farber's syndromes, metachromatic leukodystrophy,
sulfatase deficiency). Choriocarcinoma is an exception
with the ICD-10 code C58, but the number of deaths each
year is so small (one or two) that coding errors become an
important concern. Consequently, we have to ask the
services to provide activity data themselves. Routine hos-
pital data systems are unreliable because of the lack of
codes for highly specialised treatments.
Finally, we regularly monitor patients' compliments and
complaints about services. The UK literature suggests
patients do not reliably judge the technical quality of their
care against objective standards [21]. However, each cen-
tre is expected to carry out a patient satisfaction survey
every three years, because we believe this gives an indica-
tion of the quality of the process of clinical care.
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